Literature DB >> 7682398

Hydroxyethylstarch deposits in human skin--a model for pruritus?

W Jurecka1, Z Szépfalusi, E Parth, W Schimetta, W Gebhart, O Scheiner, D Kraft.   

Abstract

Severe itching for unknown reasons has been reported after administration of hydroxyethylstarch (HES) in haemodilution therapy of humans. After HES treatment, vacuoles in cells of various organs in humans have been shown, predominantly affecting the mononuclear phagocyte system. These vacuoles present indirect evidence for phagocytosis of HES particles. Since phagocytosis is also known to occur in the skin, this organ might represent a target for HES deposition, resulting in subsequent release of mediators responsible for the observed itching. The aim of the present investigation was to study skin biopsies of patients, who had received HES and suffered subsequently from itch. Skin sections were investigated for morphological impairment by means of light and electron microscopy, immunohistochemistry and immunoelectron microscopy using a polyclonal anti-HES antiserum. Storage of HES was demonstrated in the skin of all patients, mainly in dermal macrophages, endothelial cells of blood and lymph vessels, some perineural cells and endoneural macrophages of larger nerve fascicles, some keratinocytes and Langerhans cells. Treatment with antihistaminic agents proved ineffective in these patients; this fits with the observation that morphological signs of histamine release from mast cells were absent. These findings indicate that other mediators from HES-affected cells must be responsible for the development of the itching. Thus, investigation of HES storage may be a useful contribution to the elucidation of release of itch mediators and induction of pruritus.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7682398     DOI: 10.1007/bf00370817

Source DB:  PubMed          Journal:  Arch Dermatol Res        ISSN: 0340-3696            Impact factor:   3.017


  20 in total

1.  Severe anaphylactoid reaction to hydroxyethyl starch.

Authors:  M J Cullen; M Singer
Journal:  Anaesthesia       Date:  1990-12       Impact factor: 6.955

2.  Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures.

Authors:  S M Hsu; L Raine; H Fanger
Journal:  J Histochem Cytochem       Date:  1981-04       Impact factor: 2.479

Review 3.  Hetastarch: an overview of the colloid and its metabolism.

Authors:  J D Hulse; A Yacobi
Journal:  Drug Intell Clin Pharm       Date:  1983-05

Review 4.  Cytokine modulation of keratinocyte cytokines.

Authors:  J Ansel; P Perry; J Brown; D Damm; T Phan; C Hart; T Luger; S Hefeneider
Journal:  J Invest Dermatol       Date:  1990-06       Impact factor: 8.551

Review 5.  Present state of intentional hemodilution.

Authors:  K Messmer; U Kreimeier; M Intaglietta
Journal:  Eur Surg Res       Date:  1986       Impact factor: 1.745

6.  Different macrophage populations distinguished by means of fluorescent polysaccharides. Recognition and properties of marginal-zone macrophages.

Authors:  J H Humphrey; D Grennan
Journal:  Eur J Immunol       Date:  1981-03       Impact factor: 5.532

7.  Antibodies against hydroxyethylstarch produced in rabbits by immunization with a protein-hydroxyetylstarch conjugate.

Authors:  A W Richter; A N de Belder
Journal:  Int Arch Allergy Appl Immunol       Date:  1976

8.  Haemodilution therapy in ischaemic stroke: plasma concentrations and plasma viscosity during long-term infusion of dextran 40 or hydroxyethyl starch 200/0.5.

Authors:  H Kroemer; A Haass; K Müller; H Jäger; E M Wagner; P Heimburg; U Klotz
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

9.  Effect of hydroxyethyl starch (HES) in reducing parasite load in experimental visceral leishmaniasis.

Authors:  J C Jarecki-Black; L Atkins; K M Pratt; S H Pepkowitz; A B Glassman
Journal:  Ann Clin Lab Sci       Date:  1986 Nov-Dec       Impact factor: 1.256

10.  Accumulation of hydroxyethyl starch (HES) in the liver of patients with renal failure and portal hypertension.

Authors:  H P Dienes; C D Gerharz; R Wagner; M Weber; H D John
Journal:  J Hepatol       Date:  1986       Impact factor: 25.083

View more
  6 in total

1.  Pharmacodynamics and organ storage of hydroxyethyl starch in acute hemodilution in pigs: influence of molecular weight and degree of substitution.

Authors:  Christoph Eisenbach; Alexander H Schönfeld; Norbert Vogt; Moritz N Wente; Jens Encke; Wolfgang Stremmel; Eike Martin; Ernst Pfenninger; Markus A Weigand
Journal:  Intensive Care Med       Date:  2007-06-07       Impact factor: 17.440

2.  Human monocytes and keratinocytes in culture ingest hydroxyethylstarch.

Authors:  Z Szépfalusi; E Parth; W Jurecka; T A Luger; D Kraft
Journal:  Arch Dermatol Res       Date:  1993       Impact factor: 3.017

3.  Hydroxyethyl starch (HES 130/0.4) impairs intestinal barrier integrity and metabolic function: findings from a mouse model of the isolated perfused small intestine.

Authors:  Yuk Lung Wong; Ingmar Lautenschläger; Heike Dombrowsky; Karina Zitta; Berthold Bein; Thorsten Krause; Torsten Goldmann; Inez Frerichs; Markus Steinfath; Norbert Weiler; Martin Albrecht
Journal:  PLoS One       Date:  2015-03-23       Impact factor: 3.240

4.  Adverse effects of hydroxyethyl starch (HES 130/0.4) on intestinal barrier integrity and metabolic function are abrogated by supplementation with Albumin.

Authors:  Yuk Lung Wong; Ingmar Lautenschläger; Karina Zitta; Christin Schildhauer; Kerstin Parczany; Christoph Röcken; Markus Steinfath; Norbert Weiler; Martin Albrecht
Journal:  J Transl Med       Date:  2016-02-27       Impact factor: 5.531

Review 5.  Accumulation of hydroxyethyl starch in human and animal tissues: a systematic review.

Authors:  Christian J Wiedermann; Michael Joannidis
Journal:  Intensive Care Med       Date:  2013-11-21       Impact factor: 17.440

6.  Systematic review of randomized clinical trials on the use of hydroxyethyl starch for fluid management in sepsis.

Authors:  Christian J Wiedermann
Journal:  BMC Emerg Med       Date:  2008-01-24
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.